Ant International Pushes AI Strategy with AI Platform for Fintechs
4.6.2025 05:00:00 CEST | Business Wire | Press Release
Ant International, a leading global digital payment, and financial technology provider, today unveils its AI strategy with the launch of Alipay+ GenAI Cockpit, an AI-as-a-Service (AIaaS) platform that empowers fintech companies and super apps to build AI-agentic and ultimately AI-native financial services with enhanced efficiency, security, and flexibility.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20250603232250/en/
Ant International launches Alipay+ GenAI Cockpit, an AI-as-a-Service (AIaaS) platform that empowers fintech companies and super apps to build AI-agentic and ultimately AI-native financial services with enhanced efficiency, security, and flexibility.
Making AI systemically work for finance remains the holy grail of the current AI revolution. Alipay+ GenAI Cockpit is a platform to help entrepreneurs architect an agentic and ultimately AI-native financial services, combining automated workflows and task orchestration with a dynamic enterprise context, across main fintech tasks, from payment orchestration, customer onboarding, compliance checks, to fraud detection, dispute resolution, as well as evaluation and performance optimization.
“The future of finance will be shaped by agentic AI that not only carry out tasks autonomously in real automated workflows and sophisticated financial business and compliance context with reliability, but also interact, evolve and learn rapidly in orchestration with ever-growing precision,” said Jiangming Yang, Chief Innovation Officer of Ant International.
Alipay+ GenAI Cockpit has been honed on Ant International’s four key business units: wallet gateway service (Alipay+), merchant payment service (Antom), cross-border business account service (WorldFirst), and embedded finance service (global treasury management, digital lending and credit tech solutions). Upon successful completion of trial runs, the first external clients in Southeast Asia and South Asia will start officially deploying the Cockpit in June 2025.
Three-Pronged AI Strategy: Security, Vertical Fintech Expertise, and Platform-level Support for Agentic FinAI
Combining a fintech-specific toolbox and dynamic industry knowledge base alongside business-ready AI innovations, the Cockpit embodies three key directions of Ant International’s AI strategy.
Security Shield for Trusted AI
AI scamming threats using deepfake and other technologies have been growing over 10 folds by the year, with grave implications especially in the financial sector. Statistics show 22% of businesses have encountered AI-generated payment fraud.1
Ant International invests heavily in AI security solutions to combat external AI scamming attacks and eliminate internal model security risks such as model hallucination or bias. Its AI SHIELD framework manages risks across system architecture designing, data processing, model training, and inferencing. It offers real-time dynamic risk assessment, including detecting adversarial prompts and sensitive data leakage through over 100 recognition models and 600,000 risk lexicons. Today, fraud loss rate in Ant International’s merchant payment service is 5% of industry average.
Deep Vertical Financial Expertise
Alipay+ GenAI Cockpit leverages over 20 leading LLMs, including Ant International’s own Falcon Time-Series-Transformer FX Model. However, it has focused on integrating fintech knowledge bases, such as bank transfer rules and dispute resolution policies, to help businesses build specialized fintech agents.
The Cockpit toolbox supports retrieval-augmented generation (RAG), post-training, evaluation, and benchmarking, taking the combination of general-purpose datasets with industry-specific benchmarks developed from Ant International’s financial expertise to help improve model precision.
Built on the Cockpit, Antom Copilot is the world’s first AI agent designed to help merchants boost conversion by streamlining the process of payment method integration, recommending optimal payment channels, and resolving common tasks like code correction and the auto-completion of merchant onboarding documents. It also allows merchants to configure risk management strategy with natural language.
Full-Stack FinAI Platform Support
Cockpit offers a wide selection of pre-built agents covering regular tasks including customer service, content curation for targeted marketing, and AI-assisted coding. One level up, a business can easily customize agents for more specialized scenarios such as travel advisory, tax refunds, cross-border remittance, and loyalty rewards, accelerating time-to-value across business functions.
Further, the Cockpit’s model context protocol (MCP) marketplace supports major MCP servers developed thus far and allows businesses to create their own MCP servers to enable autonomous task completion. It also supports flexible deployment across public clouds and on-premise environments, drawing on strategic partnerships with Google Cloud and other top-tier infrastructure providers.
“The FinAI sector is at its big-bang moment,” said Yang. “We are eager to work with the industry to evolve and expand the toolbox as well as this ecosystem to help financial businesses scale their growth faster and better.”
About Ant International
With headquarters in Singapore and main operations across Asia, Europe, the Middle East and Latin America, Ant International is a leading global digital payment, digitisation and financial technology provider. Through collaboration across the private and public sectors, our unified techfin platform supports financial institutions and merchants of all sizes to achieve inclusive growth through a comprehensive range of cutting-edge digital payment and financial services solutions. To learn more, please visit https://www.ant-intl.com/.
____________________ |
View source version on businesswire.com: https://www.businesswire.com/news/home/20250603232250/en/
Contacts
Media Contact
Ant International
Janice Chen
janicechen.cyh@ant-intl.com
(c) 2024 Business Wire, Inc., All rights reserved.
Business Wire, a Berkshire Hathaway company, is the global leader in multiplatform press release distribution.
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Phase 3 RAINIER Results Supporting Best-in-Class Potential of Povetacicept in IgA Nephropathy Published in the New England Journal of Medicine and Presented at the American Society of Nephrology Kidney Week 202623.10.2026 19:42:00 CEST | Press Release
Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) today announced the publication of Phase 3 RAINIER results for povetacicept in the New England Journal of Medicine (NEJM), presentation of these data at the American Society of Nephrology (ASN) Kidney Week 2026 in Denver, Colorado, and advancement of the povetacicept clinical research program in IgAN. Vertex will also host an investor event during ASN on October 23 at 6:15-7 p.m. MDT (8:15-9 p.m. EDT). Further details are below. Data being presented include a pre-specified Week 36 interim analysis of the ongoing Phase 3 RAINIER trial of povetacicept, an engineered fusion protein and dual inhibitor of the BAFF (B cell activating factor) and APRIL (a proliferation inducing ligand) cytokines, in immunoglobulin A nephropathy (IgAN). RAINIER met its primary endpoint, with povetacicept achieving a 52.0% reduction from baseline in proteinuria at Week 36 and a statistically significant and clinically meaningful 49.8% reduction versus placebo (
Lifezone Metals Confirms Advanced Negotiations with Orion CMC on Kabanga Nickel Project23.10.2026 16:19:00 CEST | Press Release
Lifezone Metals Limited (NYSE: LZM) notes comments made today by Oskar Lewnowski, Founder and Group Chief Executive of Orion Resource Partners, in an interview with Bloomberg Television regarding the Company’s Kabanga Nickel Project in Tanzania. In response to inbound inquiries from media outlets and investors following the interview, the Company can confirm that negotiations with Orion Critical Mineral Consortium (Orion CMC) regarding a significant equity investment into the Kabanga Nickel Project are at an advanced stage. The Orion CMC is a global investment platform launched by Orion Resource Partners in partnership with the U.S. International Development Finance Corporation (DFC) and Abu Dhabi's sovereign investor ADQ. As previously announced, the Company has been running a competitive process, led by Standard Chartered Bank, to secure a strategic investment into the Kabanga Nickel Project. Social Media LinkedIn | X | YouTube About Lifezone Metals Lifezone Metals (NYSE: LZM) is com
BeOne Medicines Reports Sustained Survival Benefit with TEVIMBRA-ZIIHERA Combination in First-Line HER2+ Gastroesophageal Cancer23.10.2026 16:15:00 CEST | Press Release
BeOne Medicines Ltd. (Nasdaq: ONC; HKEX: 06160; SSE: 688235), a global oncology company, today announced new survival results from the planned second interim analysis (IA2) and final formal analysis of the Phase 3 HERIZON-GEA-01 trial, further confirming the benefit of TEVIMBRA® (tislelizumab) plus ZIIHERA® (zanidatamab) and chemotherapy as first-line treatment for patients with HER2-positive locally advanced or metastatic gastroesophageal adenocarcinoma (GEA). The results will be presented today as a late-breaking abstract during a rapid oral session at the European Society for Medical Oncology (ESMO) Congress 2026 in Madrid, Spain (LBA79). Mark Lanasa, M.D., Ph.D., Chief Medical Officer, Solid Tumors at BeOne, said: “Following the U.S. approval in August, these longer-term data provide further evidence supporting TEVIMBRA plus ZIIHERA and chemotherapy as the new standard of care in all first-line HER2-positive advanced gastroesophageal adenocarcinoma patients, regardless of PD-L1 sta
inDrive and Pony.ai Announce Collaboration to Explore Autonomous Mobility in Kazakhstan Built on NVIDIA Hyperion23.10.2026 15:00:00 CEST | Press Release
inDrive, the global mobility and delivery platform, today announced it has signed a memorandum of understanding (MOU) with NVIDIA and Pony.ai, a global leader in the large-scale commercialization of autonomous driving technology, to explore the future of autonomous ride-hailing. Kazakhstan will serve as the first test market. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20261023143469/en/ inDrive partners with Pony.ai and NVIDIA to explore autonomous mobility in Kazakhstan Kazakhstan was chosen first for its regulatory readiness following the creation of the country’s first structured legal framework for driverless transport, as part of its “Year of Digitalization and Artificial Intelligence.” Combined with Kazakhstan’s position as a leading Central Asian economy, this gives the companies a clear basis to assess autonomous ride-hailing in practice. The three companies will evaluate the technical, operational, regulatory and
Brenus Pharma's Novel In Vivo Immunotherapy STC-1010 Shows Safety, Activating T Cells in First-Line MSS Metastatic Colorectal Cancers With 2 Complete Responses.23.10.2026 14:50:00 CEST | Press Release
Brenus Pharma, a clinical-stage biotech company, announced first data from the Phase Ia dose escalation of BreAK CRC-001. Nine unresectable patients were treated; 89% had liver metastases and 89% KRAS-mutant tumors, a population refractory to immunotherapy. Median follow-up: 8 months (1–14; data cut-off 6/08/2026). 95% of metastatic colorectal cancers are pMMR/MSS tumors, poorly immunogenic and resistant to immunotherapy. STC-1010, the company’s lead in vivo DC-engager, is designed to make these “cold” tumors visible to immune cells. Safety: no dose-limiting toxicity, only grade 1–2 related adverse events. Clinical activity (seven evaluable patients, RECIST 1.1): 100% disease control, 57% objective response rate (4/7). 43% of patients became operable (3/7): two with no evidence of disease afterward. Molecular profile: ctDNA dropped by up to 97% within two months, TP53 and KRAS mutations near undetectable. Immune activity (first six patients): STC-1010 regimen nearly quadrupled cytotoxi
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom